Rifapentine
Priftin (rifapentine) is a small molecule pharmaceutical. Rifapentine was first approved as Priftin on 1998-06-22. It is used to treat latent tuberculosis, mycobacterium infections, and pulmonary tuberculosis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Priftin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifapentine
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PRIFTIN | Sanofi | N-021024 RX | 1998-06-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
priftin | New Drug Application | 2023-06-06 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 8 | 7 | 5 | 3 | 8 | 30 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 3 | 8 | 1 | 1 | 4 | 16 |
Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 1 | 4 | 1 | 5 | 11 | |
Infections | D007239 | EFO_0000544 | 3 | — | 1 | 2 | — | 6 | |
Mycobacterium avium complex | D015269 | 1 | — | — | 1 | — | 2 | ||
Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | 1 | — | 2 |
Drug interactions | D004347 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mycoses | D009181 | B35-B49 | 1 | — | 1 | — | — | 2 | |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | — | — | 1 |
Helicobacter infections | D016481 | EFO_1000961 | — | — | 1 | — | — | 1 | |
Gastritis | D005756 | EFO_0000217 | K29.7 | — | — | 1 | — | — | 1 |
Nontuberculous mycobacterium infections | D009165 | EFO_0007461 | A31.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv | D006678 | O98.7 | 1 | 2 | — | — | — | 3 | |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | 1 | 2 |
Coronary disease | D003327 | — | 1 | — | — | — | 1 | ||
Chlamydophila infections | D023521 | EFO_1000863 | — | 1 | — | — | — | 1 | |
Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
Bacterial infections | D001424 | A49 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | RIFAPENTINE |
INN | rifapentine |
Description | Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. In active tuberculosis it is used together with other antituberculosis medications. In latent tuberculosis it is typically used with isoniazid. It is taken by mouth.
|
Classification | Small molecule |
Drug class | antibiotics (rifamycin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
Identifiers
PDB | — |
CAS-ID | 61379-65-5 |
RxCUI | 35617 |
ChEMBL ID | CHEMBL1660 |
ChEBI ID | 45304 |
PubChem CID | 5462354 |
DrugBank | DB01201 |
UNII ID | XJM390A33U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,795 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,405 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more